Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Targeting MDSC for Immune-Checkpoint Blockade in Cancer Immunotherapy: Current Progress and New Prospects
Tianhang Li, Tianyao Liu, Wenjie Zhu, et al.
Clinical Medicine Insights Oncology (2021) Vol. 15
Open Access | Times Cited: 69

Showing 1-25 of 69 citing articles:

Myeloid-derived suppressor cells: an emerging target for anticancer immunotherapy
Yuze Wu, Ming Yi, Mengke Niu, et al.
Molecular Cancer (2022) Vol. 21, Iss. 1
Open Access | Times Cited: 247
Myeloid cell-targeted therapies for solid tumours
Sangeeta Goswami, Swetha Anandhan, Deblina Raychaudhuri, et al.
Nature reviews. Immunology (2022) Vol. 23, Iss. 2, pp. 106-120
Closed Access | Times Cited: 146
Myeloid-derived suppressor cells in cancer and cancer therapy
Samantha Lasser, Feyza Gül Özbay Kurt, Ihor Arkhypov, et al.
Nature Reviews Clinical Oncology (2024) Vol. 21, Iss. 2, pp. 147-164
Closed Access | Times Cited: 136
Targeting MHC-I molecules for cancer: function, mechanism, and therapeutic prospects
Xiangyu Wu, Tianhang Li, Rui Jiang, et al.
Molecular Cancer (2023) Vol. 22, Iss. 1
Open Access | Times Cited: 70
CXCR2 antagonist navarixin in combination with pembrolizumab in select advanced solid tumors: a phase 2 randomized trial
Andrew J. Armstrong, Ravit Geva, Hyun Cheol Chung, et al.
Investigational New Drugs (2024) Vol. 42, Iss. 1, pp. 145-159
Open Access | Times Cited: 25
Cellular interactions in tumor microenvironment during breast cancer progression: new frontiers and implications for novel therapeutics
Tosin Akinsipe, Rania Mohamedelhassan, Ayuba Akinpelu, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 18
MDSC checkpoint blockade therapy: a new breakthrough point overcoming immunosuppression in cancer immunotherapy
Abdulrahman Ibrahim, Nada Mohamady Farouk Abdalsalam, Zihao Liang, et al.
Cancer Gene Therapy (2025)
Open Access | Times Cited: 2
Targeting tumor immunosuppressive microenvironment for pancreatic cancer immunotherapy: Current research and future perspective
Ying Li, Shuai Xiang, Wenjun Pan, et al.
Frontiers in Oncology (2023) Vol. 13
Open Access | Times Cited: 32
Uncovering the spatial landscape of molecular interactions within the tumor microenvironment through latent spaces
Atul Deshpande, Melanie Loth, Dimitrios N. Sidiropoulos, et al.
Cell Systems (2023) Vol. 14, Iss. 4, pp. 285-301.e4
Open Access | Times Cited: 24
Immunotherapy resistance in solid tumors: mechanisms and potential solutions
Daniel S. Lefler, Steven Manobianco, Babar Bashir
Cancer Biology & Therapy (2024) Vol. 25, Iss. 1
Open Access | Times Cited: 15
Novel therapeutic strategies targeting myeloid-derived suppressor cell immunosuppressive mechanisms for cancer treatment
Eric Jou, Natasha Chaudhury, Fizza Nasim
Exploration of Targeted Anti-tumor Therapy (2024) Vol. 5, Iss. 1, pp. 187-207
Open Access | Times Cited: 10
Depletion of myeloid-derived suppressor cells sensitizes murine multiple myeloma to PD-1 checkpoint inhibitors
Wei Xiong, Liuling Xiao, Rui Duan, et al.
Journal for ImmunoTherapy of Cancer (2025) Vol. 13, Iss. 1, pp. e008979-e008979
Open Access | Times Cited: 1
Oncogenic Mutations and the Tumor Microenvironment: Drivers of Non-Small Cell Lung Cancer Progression
Achilleas Mitrakas, Christos Kakouratos, Ioannis Lamprou, et al.
Cancers (2025) Vol. 17, Iss. 5, pp. 853-853
Open Access | Times Cited: 1
Inhibiting the biogenesis of myeloid-derived suppressor cells enhances immunotherapy efficacy against mammary tumor progression
Sean Colligan, Andrea M. Amitrano, Robert Zollo, et al.
Journal of Clinical Investigation (2022) Vol. 132, Iss. 23
Open Access | Times Cited: 29
Immunotherapy Innovations in the Fight against Osteosarcoma: Emerging Strategies and Promising Progress
Shigao Cheng, Huiyuan Wang, Xuejia Kang, et al.
Pharmaceutics (2024) Vol. 16, Iss. 2, pp. 251-251
Open Access | Times Cited: 7
The immunosuppressive landscape in tumor microenvironment
Wuyi Liu, Huyue Zhou, Wenjing Lai, et al.
Immunologic Research (2024) Vol. 72, Iss. 4, pp. 566-582
Closed Access | Times Cited: 7
Targeting depletion of myeloid-derived suppressor cells potentiates PD-L1 blockade efficacy in gastric and colon cancers
Yaoliang Tang, Cong Zhou, Qingli Li, et al.
OncoImmunology (2022) Vol. 11, Iss. 1
Open Access | Times Cited: 27
Fatty Acid Metabolism in Myeloid-Derived Suppressor Cells and Tumor-Associated Macrophages: Key Factor in Cancer Immune Evasion
Sophiya Siddiqui, Rainer Glauben
Cancers (2022) Vol. 14, Iss. 1, pp. 250-250
Open Access | Times Cited: 26
Pan-Cancer and Single-Cell Analysis Reveals CENPL as a Cancer Prognosis and Immune Infiltration-Related Biomarker
Ziyang Feng, Yu Chen, Changjing Cai, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 24
p53 mutation and deletion contribute to tumor immune evasion
Si‐Yang Maggie Liu, Tianyao Liu, Jiaxuan Jiang, et al.
Frontiers in Genetics (2023) Vol. 14
Open Access | Times Cited: 15
Targeting inflamed and non-inflamed melanomas: biological background and clinical challenges
Alice Indini, Daniela Massi, Matteo Pirro, et al.
Seminars in Cancer Biology (2022) Vol. 86, pp. 477-490
Open Access | Times Cited: 20
Myeloid derived suppressor cells and innate immune system interaction in tumor microenvironment
Anik Pramanik, Sankar Bhattacharyya
Life Sciences (2022) Vol. 305, pp. 120755-120755
Closed Access | Times Cited: 20
Cancer immune exclusion: breaking the barricade for a successful immunotherapy
Sofía Bruni, María F. Mercogliano, Florencia Mauro, et al.
Frontiers in Oncology (2023) Vol. 13
Open Access | Times Cited: 11
Metal-Based Nanoparticles for Cancer Metalloimmunotherapy
I. Suliman, K. H. Kim, Weihsuan Chen, et al.
Pharmaceutics (2023) Vol. 15, Iss. 7, pp. 2003-2003
Open Access | Times Cited: 11
Limitations and potential of immunotherapy in ovarian cancer
Sandeep Kumar, Sayanti Acharya, Mahalakshmi Karthikeyan, et al.
Frontiers in Immunology (2024) Vol. 14
Open Access | Times Cited: 4
Page 1 - Next Page

Scroll to top